The ferment in the pharmaceutical world continues. Johnson & Johnson announces that it has signed an agreement for the acquisition of Momenta Pharmaceuticals with the aim of expanding into the field of treatments for autoimmune diseases. The value of the transaction is equal to approx 6,5 billion dollars. In detail, Johnson & Johnson is offering $52,50 for each Momenta share, a figure that incorporates a 70,4% premium on the last closing price.
Specifically, the agreement gives Janssen, a unit of Johnson & Johnson, access to nipocalimab, Momenta's investigational therapy being tested for myasthenia gravis, a neuromuscular disease that causes weakness in the muscles. The drug was developed to treat diseases in which the antibodies themselves attack or damage proteins and cells. The deal is expected to be finalized in the second half of 2020.
A few days ago the French Sanofi had announced the acquisition of the American company Principia Biopharma.
